UA110505C2 - Імуногенні композиції bordetella bronchiseptica - Google Patents

Імуногенні композиції bordetella bronchiseptica

Info

Publication number
UA110505C2
UA110505C2 UAA201309553A UAA201309553A UA110505C2 UA 110505 C2 UA110505 C2 UA 110505C2 UA A201309553 A UAA201309553 A UA A201309553A UA A201309553 A UAA201309553 A UA A201309553A UA 110505 C2 UA110505 C2 UA 110505C2
Authority
UA
Ukraine
Prior art keywords
canine
immunogenic composition
bordetella bronchiseptica
composition containing
vinakhid
Prior art date
Application number
UAA201309553A
Other languages
English (en)
Inventor
Omar Yousif Abdelmagid
Josef Michael Bricker
Shelly Lynn Shields
Jeffrey E Galvin
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of UA110505C2 publication Critical patent/UA110505C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/098—Brucella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K2039/10—Brucella; Bordetella, e.g. Bordetella pertussis; Not used, see subgroups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Винахід належить до імуногенної композиції, що містить Bordetella bronchiseptica та виділений антиген пертактину р68. Також вакцина може додатково містити антигени вірусу собачого парагрипу (CPIV), собачого аденовірусу серотипу 2 (CAV-2), собачого респіраторного коронавірусу собак (CRCoV) та Mycoplazma cynis. Винахід також належить до застосування заявленої композиції для лікування та запобіганні виникненню респіраторних інфекцій у собак.
UAA201309553A 2011-02-04 2012-03-02 Імуногенні композиції bordetella bronchiseptica UA110505C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161439597P 2011-02-04 2011-02-04
PCT/IB2012/050512 WO2012104821A1 (en) 2011-02-04 2012-02-03 Immunogenic bordetella bronchiseptica compositions

Publications (1)

Publication Number Publication Date
UA110505C2 true UA110505C2 (ru) 2016-01-12

Family

ID=45755432

Family Applications (2)

Application Number Title Priority Date Filing Date
UAA201309552A UA110504C2 (ru) 2011-02-04 2012-03-02 Композиції для комплексу респіраторних захворювань собак
UAA201309553A UA110505C2 (ru) 2011-02-04 2012-03-02 Імуногенні композиції bordetella bronchiseptica

Family Applications Before (1)

Application Number Title Priority Date Filing Date
UAA201309552A UA110504C2 (ru) 2011-02-04 2012-03-02 Композиції для комплексу респіраторних захворювань собак

Country Status (26)

Country Link
US (1) US20130302369A1 (ru)
EP (2) EP2670432B1 (ru)
JP (1) JP5833145B2 (ru)
KR (1) KR101647180B1 (ru)
CN (2) CN107296955B (ru)
AU (2) AU2012213035A1 (ru)
BR (1) BR112013019675B8 (ru)
CA (1) CA2826060C (ru)
CL (1) CL2013002219A1 (ru)
CO (1) CO6791568A2 (ru)
CY (1) CY1124093T1 (ru)
DK (1) DK2670432T3 (ru)
ES (1) ES2869175T3 (ru)
HK (1) HK1245676A1 (ru)
HR (1) HRP20210575T1 (ru)
HU (1) HUE055669T2 (ru)
LT (1) LT2670432T (ru)
MX (1) MX347177B (ru)
PL (1) PL2670432T3 (ru)
PT (1) PT2670432T (ru)
RS (1) RS61723B1 (ru)
RU (1) RU2554480C2 (ru)
SI (1) SI2670432T1 (ru)
UA (2) UA110504C2 (ru)
WO (1) WO2012104821A1 (ru)
ZA (1) ZA201306615B (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3311827T3 (da) 2011-10-03 2023-04-03 Canqura Oncology Ab Nanopartikler, fremgangsmåde til fremstilling og anvendelse deraf som bærere for amfipatiske eller hydrofobe molekyler inden for det medicinske område, inklusiv cancerbehandling, samt fødevarerelaterede forbindelser
MX363510B (es) * 2012-05-31 2019-03-26 Zoetis Llc Vacuna con coronavirus respiratorio canino para proteccion contra infecciones de b. bronchiseptica.
CA2924526A1 (en) * 2013-09-19 2015-03-26 Paul Joseph Dominowski Water-in-oil emulsions comprising immunostimulatory oligonucleotides
EP4241853A3 (en) * 2013-11-26 2023-11-22 Zoetis Services LLC Compositions for induction of immune response
PL3244920T3 (pl) 2015-01-16 2023-09-25 Zoetis Services Llc Szczepionka przeciw pryszczycy
EP3909971A1 (en) 2020-09-28 2021-11-17 Institute of Life Sciences (ILS) Whole cell livestock vaccine for respiratory diseases

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2571618A1 (fr) 1984-10-12 1986-04-18 Virbac Ctre Rech Biolog Nouveau vaccin contre la tracheobronchite infectieuse canine et son procede de preparation
US5019388A (en) * 1986-10-14 1991-05-28 Norden Laboratories Inc. Bordetella bronchiseptica vaccine
US4888169A (en) * 1986-10-14 1989-12-19 Norden Laboratories, Inc. Bordetella Bronchiseptica vaccine
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DE69735856T2 (de) * 1996-05-31 2006-11-16 National University Of Ireland Maynooth, Maynooth Il-12 als adjuvanz für bordetella pertussis impfstoffe
SK283565B6 (sk) * 1996-07-02 2003-09-11 Connaught Laboratories Limited Multivalentná imunogénna kompozícia a jej použitie
ATE393166T1 (de) * 2000-05-25 2008-05-15 Pasteur Institut Polypeptide die polymorphismen aus bordertella pertussis, bordetella parapertussis und bordetella bronchiseptica pertactin wiederholende regionen enthalten, ihre verwendung in diagnostik und immunogene zusammensetzungen
GB0217434D0 (en) * 2002-07-27 2002-09-04 Royal Vetinary College Biological material
US20050089533A1 (en) * 2003-01-29 2005-04-28 Joseph Frantz Canine vaccines against Bordetella bronchiseptica
JP2006515024A (ja) * 2003-01-29 2006-05-18 ファイザー・プロダクツ・インク Ｂｏｒｄｅｔｅｌｌａｂｒｏｎｃｈｉｓｅｐｔｉｃａに対するイヌワクチン
GB0315323D0 (en) 2003-07-01 2003-08-06 Royal Veterinary College Vaccine composition
US8574596B2 (en) * 2003-10-02 2013-11-05 Glaxosmithkline Biologicals, S.A. Pertussis antigens and use thereof in vaccination
US7572620B2 (en) 2005-01-11 2009-08-11 Wisconsin Alumni Research Foundation H3 equine influenza A virus
CA2604488A1 (en) * 2005-04-07 2006-10-12 Pharmacia & Upjohn Company Llc Formulations and process for production of bordetella bronchiseptica p68 antigen and vaccines
US7959929B2 (en) 2005-04-21 2011-06-14 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US7384642B2 (en) 2005-08-25 2008-06-10 Merial Limited Canine influenza vaccines
KR20110126726A (ko) * 2005-10-07 2011-11-23 화이자 프로덕츠 인코포레이티드 개과 동물의 인플루엔자의 치료를 위한 백신 및 방법
US7468187B2 (en) 2005-10-18 2008-12-23 Iowa State University Research Foundation, Inc. Canine influenza virus and related compositions and methods of use
WO2007047728A2 (en) * 2005-10-20 2007-04-26 Wyeth Compositions and methods for the treatment of canine influenza virus disease
US7682619B2 (en) * 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
AU2007252296A1 (en) * 2006-05-19 2007-11-29 The Walter And Eliza Hall Institute Of Medical Research Immunogenic compositions

Also Published As

Publication number Publication date
UA110504C2 (ru) 2016-01-12
KR101647180B1 (ko) 2016-08-09
AU2017203244B2 (en) 2019-05-09
ZA201306615B (en) 2015-04-29
RS61723B1 (sr) 2021-05-31
CA2826060C (en) 2019-06-18
BR112013019675A2 (pt) 2017-01-31
LT2670432T (lt) 2021-05-25
DK2670432T3 (da) 2021-04-19
US20130302369A1 (en) 2013-11-14
HUE055669T2 (hu) 2021-12-28
KR20130118975A (ko) 2013-10-30
CL2013002219A1 (es) 2014-01-31
HK1245676A1 (zh) 2018-08-31
EP3858381A1 (en) 2021-08-04
BR112013019675B8 (pt) 2022-11-22
BR112013019675B1 (pt) 2021-06-22
RU2554480C2 (ru) 2015-06-27
WO2012104821A1 (en) 2012-08-09
CO6791568A2 (es) 2013-11-14
SI2670432T1 (sl) 2021-08-31
MX2013009012A (es) 2013-12-06
ES2869175T3 (es) 2021-10-25
CN103561763A (zh) 2014-02-05
EP2670432B1 (en) 2021-03-17
CY1124093T1 (el) 2022-05-27
JP5833145B2 (ja) 2015-12-16
CN107296955A (zh) 2017-10-27
PT2670432T (pt) 2021-05-04
RU2013136151A (ru) 2015-03-10
AU2017203244A1 (en) 2017-06-08
AU2012213035A1 (en) 2013-08-15
CA2826060A1 (en) 2012-08-09
EP2670432A1 (en) 2013-12-11
JP2014504635A (ja) 2014-02-24
HRP20210575T1 (hr) 2021-05-28
MX347177B (es) 2017-04-17
CN107296955B (zh) 2021-11-23
NZ613759A (en) 2015-09-25
PL2670432T3 (pl) 2021-10-11

Similar Documents

Publication Publication Date Title
UA110505C2 (ru) Імуногенні композиції bordetella bronchiseptica
CY1117673T1 (el) Ανασυνδυασμενα αντιγονα rsv
CL2016000240A1 (es) Composición inmunogénica de reovirus de peces (prv) que comprende ácido nucleico del prv; polipéptido; virus atenuado o inactivado del prv, uso de la composición inmunogénica que sirve para tratar afecciones de infeción por prv en un animal.
CO6491048A2 (es) Inhibidores de la replicación de los virus de la gripe
CL2013003360A1 (es) “compuestos derivados de 4-aril-n-[3-(sulfonimidoil)fenil]-1,3,5-triazin-2-amina sustituidos, inhibidores cdk; compuestos intermediarios, composición y combinación farmacéutica que los comprende; y su uso en el tratamiento de enfermedades hiperproliferativas, infecciosas inducidas por virus y/o cardiovasculares”. pct
CO6831973A2 (es) Composición inmunogénica para modulación del sistema inmune y su uso, método de tratamiento y prevención de enfermedades, método para inducir la regeneración celular y procedimiento para la reconducción de la respuesta inmune
UA118010C2 (uk) Інгібітори реплікації вірусів грипу
ME01199B (me) Nove kompozicije adjuvanta
BRPI1013394A2 (pt) "composto, composição farmacêutica, uso do composto, e, método para tratar um paciente infectado com virus da hepatite c."
EA201491548A1 (ru) 2'-замещенные карбануклеозидные аналоги для противовирусного лечения
UY32274A (es) Pestivirus quimericos
NZ603863A (en) Concentration and lyophilization of influenza vaccine antigens
CL2016000300A1 (es) Métodos terapéuticos
AR088580A1 (es) Metodos y composiciones para tratar el virus de la hepatitis c
PH12018501368A1 (en) M hyo multivalent vaccine and uses thereof
ATE549031T1 (de) Impfstoffzusammensetzung zur prävention von cmv- infektionen
CL2008003845A1 (es) Vacuna que comprende una emulsion, una bacterina tratada termicamente a 55-70°c por 5-10 horas, que comprende una suspension de bacterias muertas de la especie leptospira bratislava, y de 1 a 13 virus causantes de enfermedad porcina.
MX347911B (es) Vacuna contra virus de diarrea viral de bovinos.
CL2012003737A1 (es) Parapoxvirus recombinante que comprende un parapoxvirus y adn heterologo derivado de un virus del moquillo canino; procedimiento para preparar dicho virus; composicion inmunogénica que comprende dicho virus; uso de dicho virus para tratar animal contra enfermedad del moquillo canino.
CL2012003219A1 (es) Parapoxvirus recombinante que comprende un parapoxvirus y adn heterólogo derivado de un virus de la rabia; procedimiento de preparación de dicho parapoxvirus; composicion inmunogénica; uso de la composicion para inducir respuesta inmunitaria contra el virus de la rabia en un animal.
BR112012033121A2 (pt) métodos e composições farmacêuticas para o tratamento de infecções do trato respiratório.
EA201401202A1 (ru) ВАКЦИНАЦИЯ РЕСПИРАТОРНЫМ КОРОНАВИРУСОМ СОБАК ДЛЯ ЗАЩИТЫ ОТ ИНФЕКЦИЙ B.Bronchiseptica
MX2016000021A (es) Sirna virus especifico del dengue, estructura arn oligo helicoidal, y composicion para la supresion de proliferacion del virus del dengue que comprende la estructura arn.
MX350718B (es) Vacuna de rinitis equina.
BR112014028632A8 (pt) Composto, composição farmacêutica, e, método para preparar um composto